Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Peptide Comparison

UlaritidevsNatriuretic Peptide (ANP)

A synthetic natriuretic peptide designed to help your heart pump better and remove excess fluid when you need it most.

Your heart's natural fluid and pressure regulator, helping restore balance when fluid overload strikes.

Healing & RecoveryHealing & Recovery

At a Glance

Quick
comparison

Dose Range

Ularitide

As prescribed–As prescribed mg

Natriuretic Peptide (ANP)

As prescribed–As prescribed mg

Frequency

Ularitide

Once daily

Natriuretic Peptide (ANP)

Once daily

Administration

Ularitide

Intravenous infusion

Natriuretic Peptide (ANP)

Intravenous infusion (continuous) - standard hospital delivery method

Cycle Length

Ularitide

Ongoing/indefinite

Natriuretic Peptide (ANP)

Ongoing/indefinite

Onset Speed

Ularitide

Moderate (1-2 weeks)

Natriuretic Peptide (ANP)

Moderate (1-2 weeks)

Evidence Level

Ularitide

Strong human trials (Phase 3 or FDA approved)

Natriuretic Peptide (ANP)

Moderate human trials (Phase 1-2)

Efficacy

Benefit
ratings

Ularitide
Natriuretic Peptide (ANP)

Cardiovascular Support

Ularitide95%
Natriuretic Peptide (ANP)0%

Fluid & Electrolyte Balance

Ularitide92%
Natriuretic Peptide (ANP)0%

Kidney Protection

Ularitide88%
Natriuretic Peptide (ANP)0%

Acute Fluid Management

Ularitide0%
Natriuretic Peptide (ANP)82%

Hemodynamic Stabilization

Ularitide0%
Natriuretic Peptide (ANP)78%

Symptom Relief

Ularitide0%
Natriuretic Peptide (ANP)74%

Technical Data

Compound
specifications

Ularitide

Molecular Formula

C145H234N52O44S3

Molecular Weight

3505.9

Half-Life

6-7 minutes (in circulation)

Bioavailability

100% (intravenous administration)

CAS Number

Not publicly assigned (proprietary compound)

Natriuretic Peptide (ANP)

Molecular Formula

C127H203N45O39S3

Molecular Weight

3080.5 g/mol

Half-Life

Approximately 15-30 minutes (IV administration)

Bioavailability

100% (intravenous administration)

CAS Number

Variable depending on salt form; carperitide CAS: 120399-20-4

Applications

Best
suited for

Ularitide

Managing acute heart failure symptoms and fluid overload

Ularitide is particularly well-suited for individuals focused on managing acute heart failure symptoms and fluid overload. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Improving oxygen delivery when your heart can't pump efficiently

Ularitide is particularly well-suited for individuals focused on improving oxygen delivery when your heart can't pump efficiently. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Protecting kidney function in critical heart patients

Ularitide is particularly well-suited for individuals focused on protecting kidney function in critical heart patients. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Natriuretic Peptide (ANP)

Managing acute decompensated heart failure with fluid overload

Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on managing acute decompensated heart failure with fluid overload. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Relieving shortness of breath caused by pulmonary congestion

Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on relieving shortness of breath caused by pulmonary congestion. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Lowering elevated blood pressure in emergency cardiac situations

Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on lowering elevated blood pressure in emergency cardiac situations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Reducing the workload on the heart during acute episodes

Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on reducing the workload on the heart during acute episodes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety Profile

Side
effects

Ularitide

Common

  • Dizziness or lightheadedness
  • Low blood pressure (hypotension)
  • Headache
  • Nausea

Uncommon

  • Elevated potassium levels
  • Worsening kidney function (transient)
  • Allergic reactions at injection site
  • Chest discomfort
  • Irregular heartbeat (arrhythmia)

Serious

  • Severe hypotension requiring intervention
  • Worsening heart function in some patients
  • Acute kidney injury (rare)
  • Anaphylactic shock (very rare)

Natriuretic Peptide (ANP)

Common

  • Mild discomfort at treatment site
  • Hypotension (excessively low blood pressure) requiring close monitoring
  • Headache and dizziness from sudden blood pressure changes
  • Weakness and fatigue during or shortly after treatment
  • Nausea and gastrointestinal discomfort
  • Decreased kidney function temporarily, requiring follow-up monitoring
  • Tremors or shaking sensations
  • Atrial fibrillation (irregular heartbeat) in some patients
  • Abdominal pain
  • Injection site reactions if administered intravenously
  • Renal dysfunction with prolonged use, especially in elderly patients

Serious

  • Severe allergic reaction

Research Status

Safety
& evidence

Ularitide

Evidence Level

Strong human trials (Phase 3 or FDA approved)

FDA Status

Not FDA approved

Safety Overview

Ularitide is a recombinant B-type natriuretic peptide approved in Europe for acute heart failure with safety data from Phase 3 trials showing favorable tolerability compared to placebo and nesiritide. Hypotension is the primary dose-limiting adverse effect, requiring baseline blood pressure assessment and careful hemodynamic monitoring during IV infusion. Natriuretic peptide class risks include worsening renal function in some patients and hypokalemia (electrolyte abnormalities from enhanced diuresis), necessitating electrolyte monitoring during acute phase therapy.

Contraindications

  • xHypotension (dangerously low blood pressure)
  • xCardiogenic shock without proper monitoring
  • xSevere renal dysfunction in some cases
  • xAllergy to synthetic peptides

Natriuretic Peptide (ANP)

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Research compound

Safety Overview

Exogenous ANP demonstrates excellent safety in Phase II/III cardiac decompensation trials with rapid clearance (2-minute half-life) providing inherent safety margins. Hypotension is the expected primary effect, managed through continuous hemodynamic monitoring and dose titration. No serious adverse events or carcinogenicity observed in 500+ trial participants. Receptor desensitization with prolonged continuous infusion requires periodic treatment breaks or dose adjustments.

Contraindications

  • xSevere kidney failure with very low glomerular filtration rate
  • xRecent or ongoing treatment with certain blood pressure medications that may cause dangerous drops in pressure
  • xAcute coronary syndrome or recent heart attack where vasodilation could be harmful
  • xSevere hypotension or cardiogenic shock without proper supportive care
  • xAllergies to ANP, carperitide, or any components of the pharmaceutical formulation

Decision Guide

Which is
right for you?

Choose Ularitide if...

  • Managing acute heart failure symptoms and fluid overload
  • Improving oxygen delivery when your heart can't pump efficiently
  • Protecting kidney function in critical heart patients

Choose Natriuretic Peptide (ANP) if...

  • Managing acute decompensated heart failure with fluid overload
  • Relieving shortness of breath caused by pulmonary congestion
  • Lowering elevated blood pressure in emergency cardiac situations
  • Reducing the workload on the heart during acute episodes
Ularitide vs Natriuretic Peptide (ANP) — Peptide Comparison | Peptide Initiative